RCS - Ergomed plc - Ergomed's PrimeVigilance receives Queen's Award

ErgomedAnnouncement

23/04/2019 07:05

RNS Number : 7133W
Ergomed plc
23 April 2019
 


 
 
 
 PRESS RELEASE
 
 
Ergomed's PrimeVigilance awarded 2019 Queen's Award for Enterprise
 
Awarded for year-on-year outstanding international trade performance
 
Second Queen's Award for Enterprise following previous award in 2014 in recognition of substantial growth and commercial success
 
London, UK - 23 April 2019: Ergomed plc, (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, today announces that PrimeVigilance, its pharmacovigilance, regulatory and medical information service provider, has been awarded the Queen's Award for Enterprise for the second time reinforcing Ergomed's broad leadership position as a provider of contract services. Now in its 53rd year, the Queen's Awards for Enterprise are the most prestigious business awards in the country.
 
Ergomed's PrimeVigilance has received the 2019 Queen's Award for International Trade in recognition of its year-on-year outstanding services in the drug safety sector for its global customer base. As an International Trade winner, PrimeVigilance has demonstrated substantial growth in overseas markets and commercial success, further cementing its place as a global leader in pharmacovigilance.
 
The global pharmacovigilance market is forecast to grow to more than $8 billion by 2024 from around $3 billion in 2015, with contract outsourcing forecast to expand from around 30% of the market in 2015 to approximately 50% in 2024 (Source: Global Market Insights 2017). It is essential that outstanding companies like Ergomed are able to support these growing markets.
 
Ergomed's PrimeVigilance first received a Queen's Award for Enterprise in 2014 in recognition of its substantial growth and commercial success.
 
In addition to pharmacovigilance, Ergomed provides full CRO services across all phases of clinical development and therapeutic areas under the Ergomed brand, with a particular focus on orphan drug development.
 
Dr Miroslav Reljanović, Executive Chairman of Ergomed, commented: "We are delighted that Ergomed's PrimeVigilance has been honoured with a Queen's Award for the second time in recent years. This prestigious accolade recognises the Company's continued year-on-year international growth and reinforces Ergomed's position as a leading provider of services to the pharmaceutical industry."
 
 
Enquiries:
 



Ergomed plc


 Tel: +44 (0) 1483 402 975




Miroslav Reljanović (Executive Chairman)








Stuart Jackson (Chief Financial Officer)


















Numis Securities Limited


Tel: +44 (0) 20 7260 1000




Freddie Barnfield (Nominated Adviser)








James Black (Broker)


















Consilium Strategic Communications - for UK enquiries


Tel: +44 (0) 20 3709 5700




Chris Gardner / Mary-Jane Elliott


ergomed@consilium-comms.com




Matthew Neal / Olivia Manser


















MC Services - for Continental European enquiries


Tel: +49 211 5292 5222




Anne Hennecke







 
 
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, and a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com and https://www.primevigilance.com.
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAPGUWGCUPBGBP